HRP20201572T1 - Interleukin 15 proteinski kompleks i njegova uporaba - Google Patents
Interleukin 15 proteinski kompleks i njegova uporaba Download PDFInfo
- Publication number
- HRP20201572T1 HRP20201572T1 HRP20201572TT HRP20201572T HRP20201572T1 HR P20201572 T1 HRP20201572 T1 HR P20201572T1 HR P20201572T T HRP20201572T T HR P20201572TT HR P20201572 T HRP20201572 T HR P20201572T HR P20201572 T1 HRP20201572 T1 HR P20201572T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein complex
- soluble fusion
- fusion protein
- complex according
- seq
- Prior art date
Links
- 102000003812 Interleukin-15 Human genes 0.000 title claims 23
- 108090000172 Interleukin-15 Proteins 0.000 title claims 23
- 108020001507 fusion proteins Proteins 0.000 claims 15
- 102000037865 fusion proteins Human genes 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 8
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- -1 Cys amino acid Chemical class 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 1
- 206010023791 Large granular lymphocytosis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
Claims (18)
1. IL-15 proteinski kompleks sastoji se od topljivog fuzijskog proteina I i topljivog fuzijskog proteina II; pri čemu,
topljivi fuzijski protein I je IL-15 polipeptid ili njegov funkcionalni fragment; i topljivi fuzijski protein II je IL-15Rα polipeptid ili njegov funkcionalni fragment;
pri čemu topljivi fuzijski protein I ili topljivi fuzijski protein II imaju Cys izveden iz jedne ili više mutacija aminokiseline, i disulfidna veza nastaje uparivanjem odgovarajućeg Cys prisutnog u topljivom fuzijskom proteinu II i topljivom fuzijskom proteinu I;
pri čemu Cys mutacija aminokiseline nastaje na L45, Q48, V49, L52, E53, C88 ili E89 na IL-15 polipeptidu ili njegovom funkcionalnom fragmentu; i/ili pri čemu Cys mutacija aminokiseline nastaje na K34, L42, A37, G38, ili S40 na IL-15Rα polipeptidu ili njegovom funkcionalnom fragmentu.
2. IL-15 proteinski kompleks sukladno patentnom zahtjevu 1, pri čemu topljivi fuzijski protein I i/ili topljivi fuzijski protein II je kovalentno spojen na Fc fragment ili njegov mutant.
3. IL-15 proteinski kompleks sukladno patentnom zahtjevu 1, pri čemu Cys mutacija aminokiseline nastaje na L52 na IL-15 polipeptidu ili njegovom funkcionalnom fragmentu; i/ili pri čemu Cys mutacija aminokiseline nastaje na S40 na IL-15Rα polipeptidu ili njegovom funkcionalnom fragmentu.
4. IL-15 proteinski kompleks sukladno patentnom zahtjevu 1, pri čemu sekvenca topljivog fuzijskog proteina I je SEK ID BR: 2.
5. IL-15 proteinski kompleks sukladno bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je topljivi fuzijski protein II načinjen rekombinacijom IL-15Rα polipeptida ili njegovog funkcionalnog fragmenta i Fc fragmenta.
6. IL-15 proteinski kompleks sukladno patentnom zahtjevu 5, pri čemu IL-15Rα polipeptid ili njegov funkcionalni fragment je spojen na N-terminus Fc fragmenta.
7. IL-15 proteinski kompleks sukladno patentnom zahtjevu 5, pri čemu je Fc fragment prikazan u SEK ID BR: 9.
8. IL-15 proteinski kompleks sukladno patentnom zahtjevu 6, pri čemu je Fc fragment prikazan u SEK ID BR: 9.
9. IL-15 proteinski kompleks sukladno bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je sekvenca topljivog fuzijskog proteina II odabran iz skupine koja sadrži SEK ID BR: 5, SEK ID BR: 6, SEK ID BR: 7 i SEK ID BR: 8.
10. IL-15 proteinski kompleks sukladno patentnom zahtjevu 1, pri čemu je topljivi fuzijski protein I prikazan u SEK ID BR:2, i topljivi fuzijski protein II je prikazan u SEK ID BR: 5, 6, 7 ili 8.
11. Nukleinska kiselina, koja kodira IL-15 proteinski kompleks sukladno bilo kojem od patentnih zahtjeva 1 do 10.
12. DNK vektor, koji sadrži nukleinsku kiselinu sukladno patentnom zahtjevu 11.
13. Stanica domaćin, koja sadrži DNK vektor sukladno patentnom zahtjevu 12.
14. Postupak za dobivanje IL-15 proteinskog kompleksa sukladno bilo kojem od patentnih zahtjeva 1 do 10, taj postupak sadrži:
kultiviranje stanice domaćina sukladno patentnom zahtjevu 13 pod uvjetom dovoljnim za eksprimiranje IL-15 proteinskog kompleksa sukladno bilo kojem od patentnih zahtjeva 1 do 10;
eksprimiranje i pročišćavanje IL-15 proteinskog kompleksa.
15. Farmaceutski pripravak, sadrži IL-15 proteinski kompleks sukladno bilo kojem od patentnih zahtjeva 1 do 10, i farmaceutski prihvatljiv ekscipijens, razblaživač ili nosač.
16. IL-15 proteinski kompleks sukladno bilo kojem od patentnih zahtjeva 1 do 10, ili farmaceutski pripravak sukladno patentnom zahtjevu 15, za uporabu radi liječenja putem IL-15 uzrokovanih bolesti ili poremećaja;
pri čemu je bolest ili poremećaj odabran iz skupine koja sadrži infektivnu bolest, karcinom, bolest krvi, upalnu bolest i autoimunu bolest;
karcinom je poželjno odabran iz skupine koju čini melanom, kolorektalni karcinom, karcinom kože, limfom, karcinom stanice bubrega, karcinom jetre, karcinom pluća, karcinom želuca, i karcinom dojke;
infektivna bolest je poželjno odabrana iz skupine sastavljene od infekcije variola virusom, HIV infekcije, bakterijske infekcije, gljivične infekcije i HBV infekcije;
oboljenje krvi je poželjno odabrano iz skupine koju čini anemija, akutna mijeloična leukemija, mijelodisplastični sindrom, i velika granularna limfocitna leukemija T stanica.
autoimuna bolest je poželjno odabrana iz skupine koja sadrži multiple sklerozu, psorijazu, reumatoidni artritis, gastritis i mukozitis.
17. IL-15 proteinski kompleks ili farmaceutski pripravak za uporabu u liječenju sukladno patentnom zahtjevu 16, pri čemu je ta uporaba u kombinaciji s inhibitorom malih molekula ili lijek protutijelo; inhibitor male molekule je poželjno odabran iz ciljanih kemoterapijskih ili radioterapijskih agenasa; lijek protutijelo je poželjno odabrano iz monoklonalnog protutijela, još poželjnije je odabrano iz protu-CD20, protu-PD1, protu -PDL1, protu-Her2, protu-EGFR i protu-c-MET protutijela.
18. IL-15 proteinski kompleks sukladno bilo kojem od patentnih zahtjeva 1 do 10, ili farmaceutski pripravak sukladno patentnom zahtjevu 15, za uporabu u staničnoj imunoterapiji, stanična imunoterapija je specifična imunoterapija za tumor DC, CIK, DC-CIK, ECIK, NK, CAS-T, BiAb-T, TCR-T i CAR-T.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410799889 | 2014-12-19 | ||
| PCT/CN2015/094780 WO2016095642A1 (zh) | 2014-12-19 | 2015-11-17 | 白细胞介素15蛋白复合物及其用途 |
| EP15869151.9A EP3235830B1 (en) | 2014-12-19 | 2015-11-17 | Interleukin 15 protein complex and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201572T1 true HRP20201572T1 (hr) | 2020-12-11 |
Family
ID=56125866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201572TT HRP20201572T1 (hr) | 2014-12-19 | 2020-10-04 | Interleukin 15 proteinski kompleks i njegova uporaba |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10905743B2 (hr) |
| EP (1) | EP3235830B1 (hr) |
| JP (1) | JP6709456B2 (hr) |
| KR (1) | KR102609197B1 (hr) |
| CN (1) | CN106459219B (hr) |
| AU (1) | AU2015366795B2 (hr) |
| CA (1) | CA2970385C (hr) |
| CY (1) | CY1123555T1 (hr) |
| DK (1) | DK3235830T3 (hr) |
| ES (1) | ES2828037T3 (hr) |
| HR (1) | HRP20201572T1 (hr) |
| HU (1) | HUE052182T2 (hr) |
| LT (1) | LT3235830T (hr) |
| PL (1) | PL3235830T3 (hr) |
| PT (1) | PT3235830T (hr) |
| RS (1) | RS60996B1 (hr) |
| RU (1) | RU2711979C2 (hr) |
| SI (1) | SI3235830T1 (hr) |
| TW (1) | TWI714544B (hr) |
| WO (1) | WO2016095642A1 (hr) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3235830T3 (da) * | 2014-12-19 | 2020-11-09 | Jiangsu Hengrui Medicine Co | Interleukin-15-proteinkompleks og anvendelse deraf |
| EP3458092A1 (en) | 2016-05-18 | 2019-03-27 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| CR20190227A (es) * | 2016-10-14 | 2019-08-29 | Xencor Inc | Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15ra y fragmentos de anticuerpo pd-1 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3064375A1 (en) * | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy |
| WO2019006472A1 (en) * | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| JP7263312B2 (ja) * | 2017-07-25 | 2023-04-24 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Ｉｌ－１５タンパク質複合体医薬組成物およびその使用 |
| KR20210032924A (ko) | 2017-09-05 | 2021-03-25 | 토크 테라퓨틱스, 인코포레이티드 | 치료용 단백질 조성물 및 그의 제조 및 사용 방법 |
| US11866466B2 (en) | 2017-12-19 | 2024-01-09 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
| TWI776024B (zh) | 2018-02-28 | 2022-09-01 | 美商輝瑞大藥廠 | Il-15變體及其用途 |
| JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 |
| EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| CN110437339B (zh) * | 2018-05-04 | 2021-08-13 | 免疫靶向有限公司 | 一种以白介素15为活性成分的融合蛋白型药物前体 |
| CN110448691A (zh) * | 2018-05-07 | 2019-11-15 | 江苏恒瑞医药股份有限公司 | 抗pd-1抗体联合il-15蛋白复合物在制备治疗肿瘤的药物中的用途 |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| KR20210038548A (ko) | 2018-06-22 | 2021-04-07 | 큐진 인크. | 사이토카인-기반 생체활성 약물 및 이의 사용 방법 |
| CN108853143A (zh) * | 2018-07-04 | 2018-11-23 | 盛春华 | 治疗银屑病的免疫细胞制剂、其制备方法及应用 |
| EP3827079A1 (en) * | 2018-07-25 | 2021-06-02 | Askgene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| PE20211055A1 (es) | 2018-10-12 | 2021-06-07 | Xencor Inc | Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas |
| TW202028226A (zh) * | 2018-12-13 | 2020-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｉｌ－１５蛋白複合物聯合ｐｄ－ｌ１抗體用於治療腫瘤疾病的用途 |
| EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| US20220106375A1 (en) * | 2019-01-11 | 2022-04-07 | Memorial Sloan Kettering Cancer Center | Multimerization of il-15/il-15r-alpha-fc complexes to enhance immunotherapy |
| CN116574183A (zh) * | 2019-08-22 | 2023-08-11 | 盛禾(中国)生物制药有限公司 | 多功能抗体、其制备及其用途 |
| EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| RU2753282C2 (ru) | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CN113135996A (zh) * | 2019-12-09 | 2021-07-20 | 启愈生物技术(上海)有限公司 | 一种双特异抗体及其应用 |
| KR20220115611A (ko) * | 2019-12-13 | 2022-08-17 | 큐진 인크. | 사이토카인-기반 생체활성 약물 및 이의 사용 방법 |
| JP2022522566A (ja) * | 2020-02-05 | 2022-04-20 | ノバルティス アーゲー | ＣＨＯ細胞で発現されたｈｅｔ ＩＬ－１５ |
| US20230141575A1 (en) * | 2020-03-18 | 2023-05-11 | City Of Hope | Multivalent chemokine receptor binding complexes |
| EP3889183A1 (en) | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
| CN114057889B (zh) * | 2020-07-30 | 2023-11-10 | 深圳市北科生物科技有限公司 | 二硫键稳定的IL15-IL15Rα复合物及其应用 |
| KR20230096049A (ko) | 2020-10-26 | 2023-06-29 | 싸이튠 파마 | 편평 세포 암종 치료용 IL-2/IL-15Rβγ 작용제 |
| MX2023004880A (es) | 2020-10-26 | 2023-05-11 | Cytune Pharma | AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA. |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| CN113321736B (zh) * | 2020-12-30 | 2024-01-09 | 苏州复融生物技术有限公司 | 一种长效化白介素15融合蛋白及其制备方法和应用 |
| CN113106068A (zh) * | 2021-03-26 | 2021-07-13 | 深圳市先康达生命科学有限公司 | 一种自分泌IL-15与anti-PD1融合蛋白的免疫细胞 |
| TW202241968A (zh) * | 2021-04-22 | 2022-11-01 | 大陸商廣東菲鵬制藥股份有限公司 | 雙特異性多功能融合多肽 |
| CA3220418A1 (en) | 2021-06-23 | 2022-12-29 | Guy Luc Michel De Martynoff | Interleukin 15 variants |
| WO2023086772A1 (en) | 2021-11-12 | 2023-05-19 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| CN116496408A (zh) * | 2022-01-21 | 2023-07-28 | 广东菲鹏制药股份有限公司 | 白细胞介素21及其受体复合物 |
| CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2024102941A1 (en) * | 2022-11-11 | 2024-05-16 | Rakuten Medical, Inc. | Engineered interleukin-15 polypeptides, complexes and uses thereof |
| CN116574192A (zh) * | 2023-03-30 | 2023-08-11 | 上海妙聚生物科技有限公司 | 一种可条件性释放并激活的细胞因子融合蛋白及其制备和用途 |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| WO2024215989A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2502316A1 (en) * | 2002-10-14 | 2004-04-29 | F. Hoffmann-La Roche Ag | Antagonists il-15 |
| CN100334112C (zh) * | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| CA3028038C (en) * | 2007-05-11 | 2021-08-10 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| NZ582330A (en) * | 2007-06-27 | 2012-05-25 | Marinepolymer Tech Inc | COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF |
| KR20140020228A (ko) * | 2010-09-21 | 2014-02-18 | 알토 바이오사이언스 코포레이션 | 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| IN2015DN01361A (hr) * | 2012-08-02 | 2015-07-03 | Jn Biosciences Llc | |
| JP6359019B2 (ja) * | 2012-10-24 | 2018-07-18 | ノバルティス アーゲー | ＩＬ−１５Ｒα型、ＩＬ−１５Ｒα型を発現する細胞、ならびにＩＬ−１５ＲαおよびＩＬ−１５／ＩＬ−１５Ｒα複合体の治療上の使用 |
| JP6484634B2 (ja) * | 2014-01-08 | 2019-03-13 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Ｉｌ−１５ヘテロ二量体タンパク質及びその用途 |
| DK3235830T3 (da) * | 2014-12-19 | 2020-11-09 | Jiangsu Hengrui Medicine Co | Interleukin-15-proteinkompleks og anvendelse deraf |
-
2015
- 2015-11-17 DK DK15869151.9T patent/DK3235830T3/da active
- 2015-11-17 JP JP2017531745A patent/JP6709456B2/ja active Active
- 2015-11-17 CN CN201580022811.4A patent/CN106459219B/zh active Active
- 2015-11-17 EP EP15869151.9A patent/EP3235830B1/en active Active
- 2015-11-17 CA CA2970385A patent/CA2970385C/en active Active
- 2015-11-17 PL PL15869151T patent/PL3235830T3/pl unknown
- 2015-11-17 PT PT158691519T patent/PT3235830T/pt unknown
- 2015-11-17 ES ES15869151T patent/ES2828037T3/es active Active
- 2015-11-17 US US15/537,107 patent/US10905743B2/en active Active
- 2015-11-17 RU RU2017124289A patent/RU2711979C2/ru active
- 2015-11-17 SI SI201531372T patent/SI3235830T1/sl unknown
- 2015-11-17 AU AU2015366795A patent/AU2015366795B2/en active Active
- 2015-11-17 LT LTEP15869151.9T patent/LT3235830T/lt unknown
- 2015-11-17 KR KR1020177018986A patent/KR102609197B1/ko active IP Right Grant
- 2015-11-17 WO PCT/CN2015/094780 patent/WO2016095642A1/zh active Application Filing
- 2015-11-17 HU HUE15869151A patent/HUE052182T2/hu unknown
- 2015-11-17 RS RS20201188A patent/RS60996B1/sr unknown
- 2015-12-11 TW TW104141672A patent/TWI714544B/zh active
-
2020
- 2020-09-28 CY CY20201100911T patent/CY1123555T1/el unknown
- 2020-10-04 HR HRP20201572TT patent/HRP20201572T1/hr unknown
- 2020-12-21 US US17/129,100 patent/US11717559B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201572T1 (hr) | Interleukin 15 proteinski kompleks i njegova uporaba | |
| JP6484634B2 (ja) | Ｉｌ−１５ヘテロ二量体タンパク質及びその用途 | |
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| Suryadevara et al. | Are BiTEs the “missing link” in cancer therapy? | |
| JP2016156828A5 (hr) | ||
| CN110785435A (zh) | 与il-12和il-18的基于il-15的融合物 | |
| JP2020524174A5 (hr) | ||
| JP7579703B2 (ja) | 抗ｐｄ－ｌ１／抗ｐｄ－１天然抗体構造様ヘテロダイマー二重特異性抗体およびその調製方法 | |
| CN111655716A (zh) | 基于il-15的与il-7和il-21的融合体 | |
| RU2018147423A (ru) | Анти-PD-L1 и IL-2 цитокины | |
| JP2017532045A5 (hr) | ||
| Mitwasi et al. | Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells | |
| JP2018522564A5 (hr) | ||
| RU2014100350A (ru) | ИММУНОЦИТОКИНЫ НА ОСНОВЕ IL-15 И IL-Rα ДОМЕНА SUSHI | |
| JP2018535196A5 (hr) | ||
| JP2018537415A (ja) | 多価Ｆｖ抗体 | |
| WO2010107658A2 (en) | Methods and compositions for bi-specific targeting of cd19/cd22 | |
| Runbeck et al. | Utilizing immunocytokines for cancer therapy | |
| JP2020530770A5 (hr) | ||
| Fercher et al. | Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins | |
| US11542318B2 (en) | Use of chemokine receptor CXCR5 | |
| CN115867581A (zh) | 含有保护肽的嵌合抗原受体及其用途 | |
| HRP20191671T1 (hr) | Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) | |
| JP2021502828A (ja) | Ｉｌ−３３を分泌する免疫応答性細胞およびその使用 | |
| JP2020535832A (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |